Riverpark Capital Management LLC Purchases 276 Shares of Eli Lilly and Company $LLY

Riverpark Capital Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 8.9% in the second quarter, Holdings Channel.com reports. The fund owned 3,363 shares of the company’s stock after acquiring an additional 276 shares during the period. Eli Lilly and Company comprises 4.3% of Riverpark Capital Management LLC’s portfolio, making the stock its 6th biggest holding. Riverpark Capital Management LLC’s holdings in Eli Lilly and Company were worth $2,622,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Braun Bostich & Associates Inc. boosted its stake in Eli Lilly and Company by 2.5% in the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after purchasing an additional 13 shares during the period. Rise Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.8% during the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after buying an additional 13 shares in the last quarter. Occidental Asset Management LLC raised its position in Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares during the period. New Insight Wealth Advisors lifted its stake in Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after acquiring an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. boosted its position in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,047.50.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,109.09 on Wednesday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.11. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business’s 50 day moving average is $869.19 and its 200-day moving average is $792.66. The firm has a market capitalization of $1.05 trillion, a PE ratio of 72.49, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.